Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Significance: T cells recognize their targets via their T-cell receptors (TCRs), which in the case of CD8 + T cells bind to MHC-I:antigen complexes on the surface of target cells. Many cancer cells evade immune recognition and killing by down-regulating MHC-I AgPPM. Here, we show how the histone acetyl transferases p300/CBP together with NF-κB epigenetically regulate expression of MHC-I molecules, immunoproteasome subunits, and peptide transporter to enable proper MHC-I antigen presentation. Notably, this pathway is frequently disrupted in human cancers. We now show that certain chemotherapeutics can augment MHC-I antigen presentation via NF-κB and p300/CBP activation, thereby enhancing cancer cell recognition and killing by effector CD8 + CTLs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“However, even CTL-populated tumors can evade immune elimination either through activation of immunosuppressive mechanisms that induce CD8 T-cell suppression or restrain their entry into tumors (10), down-regulation of major histocompatibility class I (MHC-I) AgPP (11, 12), or antigen editing and loss (13).”
Self-citationElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 12×
“Tumor-infiltrating CTLs, however, were strongly increased after anti – PD-L1 + Oxali treatment as indicated by scRNA-seq and flow cytometry.”
InfluentialSelf-citationGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
ATAC-seq: a method for assaying chromatin accessibility genome-wide
Buenrostro, J. D., Wu, B., Chang, H. Y., & Greenleaf, W. J. (2015) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb2129s109 · Cited by 3,289
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · cited 12×
“Strong Oxali-induced MHC-I surface expression was detected in the human PC3 PCa cell line, PCSD1 cells, a three-dimensional (3D) organoid culture from a patient-derived xenograft (PDX) of bone metastatic PCa, certain primary melanoma cells, and MIA PaCa-2 cells, representing ICIT-refractory PDAC ( SI Appendix , Fig.”
InfluentialAdjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906 · cited 1×
“I mmune checkpoint inhibitor therapy (ICIT) had transformed cancer treatment (1 – 4), but even in ICIT-responsive metastatic melanoma and nonsmall cell lung cancer (NSCLC), response rates rarely exceed 40% (5).”
Cited by
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“DNA damage has been proven to cause elevated MHC-I [153].”
BackgroundFei, X., Huang, J., Li, F., Wang, Y., Shao, Z., Dong, L., Wu, Y., Li, B., Zhang, X., Lv, B., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112586 · Cited by 42
Self-citation
Metadata
- Authors
- Zhou, Y., Bastian, I. N., Long, M. D., Dow, M., Li, W., Liu, T., Ngu, R. K., Antonucci, L., Huang, J. Y., Phung, Q. T., Zhao, X.-H., Banerjee, S., Lin, X.-J., Wang, H., Dang, B., Choi, S., Karin, D., Su, H., Ellisman, M. H., Jamieson, C., Bosenberg, M., Cheng, Z., Haybaeck, J., Kenner, L., Fisch, K. M., Bourgon, R., Hernandez, G., Lill, J. R., Liu, S., Carter, H., Mellman, I., Karin, M., & Shalapour, S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2021-02-18
- Volume
- 118
- Issue
- 8
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3131620481
- Cited by
- 100
- References
- 25
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. https://app.cochat.ai/papers/10.1073/pnas.2025840118
- The paper
- Zhou, Y., Bastian, I. N., Long, M. D., Dow, M., Li, W., Liu, T., Ngu, R. K., Antonucci, L., Huang, J. Y., Phung, Q. T., Zhao, X.-H., Banerjee, S., Lin, X.-J., Wang, H., Dang, B., Choi, S., Karin, D., Su, H., Ellisman, M. H., . . . Shalapour, S. (2021). Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2025840118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.